Glaxo, Danone Probed as China Scrutinizes Foreign Firms

China’s probes of GlaxoSmithKline Plc and Danone highlight challenges for foreign companies in a market where they may be a bigger “prize” for regulators seeking to allay concerns that medicines and foods are unsafe.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.